Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Transplantation and cellular therapy·2026
Same author

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Blood advances·2026
Same author

Chemokine Receptor Profiles as Predictors of Survival and Early Progression in Follicular Lymphoma.

EJHaem·2025
Same author

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.

Blood·2025
Same author

Comparing functional and genomic-based precision medicine in blood cancer patients.

HemaSphere·2025
Same author

Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease.

Bone marrow transplantation·2025

Related Experiment Video

Updated: Sep 3, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Targeting the Microenvironment for Treating Multiple Myeloma.

Peter Neumeister1, Eduard Schulz1,2, Katrin Pansy1

  • 1Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036 Graz, Austria.

International Journal of Molecular Sciences
|July 27, 2022
PubMed
Summary
This summary is machine-generated.

Multiple myeloma (MM) is a deadly plasma cell cancer. Targeting the bone marrow microenvironment (BMME) offers novel therapeutic strategies, improving outcomes for patients with this incurable disease.

Keywords:
CAR T cellCD 38 antibody therapybispecific antibodydaratumumabimmunologyisatuximabmicroenvironmentmultiple myelomatargeted therapy

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Related Experiment Videos

Last Updated: Sep 3, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is a malignant, incurable plasma cell disorder.
  • MM progresses through stages: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
  • The bone marrow microenvironment (BMME) is critical for MM development and progression.

Purpose of the Study:

  • To describe the complex interplay between myeloma cells and the BMME.
  • To present novel therapeutic strategies targeting the BMME for MM care.

Main Methods:

  • Review of literature on MM pathogenesis and BMME interactions.
  • Analysis of emerging BMME-modifying therapies.

Main Results:

  • The BMME facilitates MM growth and progression.
  • Targeting the BMME is a promising therapeutic strategy.

Conclusions:

  • Understanding the MM-BMME interaction is key to developing effective treatments.
  • Novel therapies targeting the BMME significantly improve long-term outcomes for MM patients.